Table 2.

Matched cohort outcomes

Mean (SE)	Dronabinol cases (n=33)	Non-dronabinol controls (n=33)	Difference	P value
Primary outcome
Change in MME	−78.7 (20.2)	−8.6 (17.6)	−70.2 (28.8)	0.02
Change in MME*	−96.5 (24.5)	11.2 (28.4)	−107.7 (39.8)	0.01
Secondary outcomes
MME on treatment	90.0 (17.5)	121.0 (27.0)	−30.9 (33.2)	0.36
Pain NRS on treatment	5.3 (0.3)	4.3 (0.3)	0.9 (0.5)	0.07
Change in pain NRS	−0.4 (0.3)	−0.6 (0.4)	0.1 (0.5)	0.78
Change in non-opioid multimodal pain adjuncts
Acetaminophen, mg	−468 (466)	−434 (268)	−34 (485)	0.94
Cyclobenzaprine, mg	−5.5 (3.3)	0 (1.7)	−5.5 (3.5)	0.12
Methocarbamol, mg	7.6 (68)	−136 (111)	144 (130)	0.28

*Cases using marijuana (n=19) and their matched controls (n=19).

MME, morphine milligram equivalents; NRS, numeric rating score.